Literature DB >> 21225909

Strategies to manage retinoblastoma in developing countries.

Guillermo L Chantada1, Ibrahim Qaddoumi, Serife Canturk, Vikas Khetan, Zhigui Ma, Kahaki Kimani, Baris Yeniad, Iyad Sultan, Rita S Sitorus, Nurdan Tacyildiz, David H Abramson.   

Abstract

Survival of retinoblastoma is >90% in developed countries but there are significant differences with developing countries in stage at presentation, available treatment options, family compliance, and survival. In low-income countries (LICs), children present with advanced disease, and the reasons are socioeconomic and cultural. In middle-income countries (MICs), survival rates are better (>70%), but there is a high prevalence of microscopically disseminated extraocular disease. Programs for eye preservation have been developed, but toxicity-related mortality is higher. Although effective treatment of microscopically extraocular disease improved the outcome, worldwide survival will be increased only by earlier diagnosis and better treatment adherence.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21225909     DOI: 10.1002/pbc.22843

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  30 in total

1.  Extraocular retinoblastoma in Indian children: clinical, imaging and histopathological features.

Authors:  Sumita Sethi; Neelam Pushker; Seema Kashyap; Sanjay Sharma; Mridula Mehta; Sameer Bakhshi; Saurbhi Khurana; Supriyo Ghose
Journal:  Int J Ophthalmol       Date:  2013-08-18       Impact factor: 1.779

Review 2.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

Review 3.  Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma.

Authors:  Uma M Sachdeva; Joan M O'Brien
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

4.  Preserving vision in retinoblastoma through early detection and intervention.

Authors:  Sidnei Epelman
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

5.  The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience.

Authors:  Flavio Requejo; Juan Marelli; Agustin Ruiz Johnson; Claudia Sampor; Guillermo Chantada
Journal:  Interv Neuroradiol       Date:  2017-11-09       Impact factor: 1.610

6.  "Retinoblastoma survival disparity": The expanding horizon in developing countries.

Authors:  Masood Naseripour
Journal:  Saudi J Ophthalmol       Date:  2012-02-18

7.  Developmental Delay and School Performance Among Retinoblastoma Survivors: Development/school morbidity among retinoblastoma survivors.

Authors:  Margaret Reynolds; Gregg Lueder; Mae Gordon; Robert J Hayashi
Journal:  Am J Ophthalmol       Date:  2021-05-07       Impact factor: 5.488

8.  lncRNA MALAT1 regulated ATAD2 to facilitate retinoblastoma progression via miR-655-3p.

Authors:  Yuxin Zhao; Zhaoxia Wang; Meili Gao; Xuehong Wang; Hui Feng; Yuanyuan Cui; Xia Tian
Journal:  Open Med (Wars)       Date:  2021-06-24

9.  A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma.

Authors:  Jeni P Mahida; Christophe Antczak; Daniel Decarlo; Kathryn G Champ; Jasmine H Francis; Brian Marr; Arthur S Polans; Daniel M Albert; David H Abramson; Hakim Djaballah
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Integrating stages of change models to cast new vision on interventions to improve global retinoblastoma and childhood cancer outcomes.

Authors:  Meaghann S Weaver; Christina L Heminger; Catherine G Lam
Journal:  BMC Public Health       Date:  2014-09-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.